title: [Induction of LAK cells by high density dialyzing culture device and its cytotoxicity].
abstract: Lymphokine activated killer (LAK) cells are generated by culture of lymphocytes with interleukin 2 (IL-2) in short term culture (3 to 5 days) and are used for adoptive immunotherapy for advanced cancer patients. The culture condition hitherto reported are essentially based on the rotating culture system, in which the maximum cell density was at 2 X 10(6) cell/ml and the cell recovery was usually less than 100%. The inability to induce LAK cells efficiently in vitro made the culturing of cells for therapy rather difficult and costly work because the mean infusion dose of LAK cells of one patient requires more than 1 X 10(10)/ml. We have therefore attempted to culture lymphocytes in 10 times higher concentration comparing with conventional methods. By using a new dialyzing culture system under continuous regulation of the amount of infused IL-2, nutrition medium, and pO2 and pCO2, we could culture cells at 2 X 10(7)/ml for more than 21 days and the resulted LAK cells showed a 100 times increase of activity on a per cell basis. By limiting dilution procedure, these killer cells mostly express T cell markers such as CD3 and CD8 but dose not express CD16.
authors.affiliation: Fourth Department of Internal Medicine, Sapporo Medical College.
authors.forename: Y
authors.initials: Y
authors.lastname: Kohgo
authors.forename: Y
authors.initials: Y
authors.lastname: Kanisawa
authors.forename: S
authors.initials: S
authors.lastname: Sakamaki
authors.forename: S
authors.initials: S
authors.lastname: Nojiri
authors.forename: Y
authors.initials: Y
authors.lastname: Ueno
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Niitsu
authors.forename: S
authors.initials: S
authors.lastname: Hosoi
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: I
authors.initials: I
authors.lastname: Urushizaki
mesh_terms: D002455:Cell Division; D003584:Cytological Techniques / Q000295:instrumentation*; D003602:Cytotoxicity, Immunologic; D003956:Dialysis / Q000295:instrumentation*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000276:immunology*; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins